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BACKGROUND: Securin is a recently recognised oncogene with multiple known functions in initiation, progression and cell cycle
regulation in several malignant diseases, including breast carcinoma.
METHODS: In this paper, the prognostic value of securin is evaluated by immunohistochemistry in 310 patients diagnosed with invasive
breast cancer during a mammographic screening programme in Central Finland. All patients were directed to modern surgical and
oncological treatments and were followed up for a maximum of 20 years.
RESULTS: Our results suggest that securin immunopositivity is an independent prognosticator of invasive breast cancer. In our study,
securin predicted breast cancer-specific survival among all cases of invasive breast cancer and subgroups divided according to
histological type, Ki-67 proliferation status and tumour size. Especially in a multivariate analysis standardised for axillary lymph node
status, patient’s age and tumour size at the time of diagnosis, securin immunopositivity indicated a 13.1-fold risk of breast cancer death
(P¼0.024) among invasive ductal breast carcinomas with low Ki-67 positivity.
CONCLUSION: Our present and previous results suggest that securin could be useful in clinical pathology to intensify the power of the
established prognosticators of invasive breast cancer and, especially, to assist in identifying patients with a more favourable outcome
than that indicated by Ki-67 alone.
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Despite advances in diagnostics, treatment and overall prognosis
of breast cancer, the outcome of individual breast cancer patients
may still be unpredictable and relapses occur after several years
from primary treatment (Thompson et al, 2008). In recent years,
features underlying the heterogeneous behaviour of breast cancer
have been addressed with the help of modern methods of
molecular pathology and histopathology (van de Vijver et al,
2002; Rakha et al, 2008; Geyer et al, 2009). In several investiga-
tions, uncontrolled mitotic activity has been recognised as being
among the most important factors influencing breast cancer
development and progression (Stuart-Harris et al, 2008; Baak et al,
2009). Uncontrolled aberrant mitotic divisions leading to aneu-
ploidy have been suggested in literature as being one of the most
common characteristics of any cancer cell and also with a strong
influence on the behaviour of breast cancer (Bharadwaj and Yu,
2004; Kops et al, 2005). This paper reports on the role of securin
(pituitary tumour transforming gene, PTTG1) in estimating
proliferative activity and prognosis in breast cancer. Securin is
an oncogene with a known role in cell cycle regulation and
maintenance of chromosomal integrity (Tfelt-Hansen et al, 2006;
Bradshaw and Kakar, 2007; Salehi et al, 2008).
Securin was first isolated in rat pituitary tumour cells
(Domı ´nguez et al, 1998). Thereafter, securin has been identified
in human tissues with a low expression in normal cells but elevated
expressions in proliferating cells of several malignant tumours. To
date, securin has been reported to be overexpressed, especially in
endocrine-related tumours such as thyroid, breast, ovarian and
uterine carcinomas, and also in non-endocrine tumours such as
pulmonary and gastrointestinal carcinomas and malignancies of
the central nervous system (Shibata et al, 2002; Solbach et al, 2004;
Wen et al, 2004; Ogbagabriel et al, 2005; Salehi et al, 2008). Securin
is a multidomain and multifunctional protein identified with roles
in cell cycle, cellular transformation, tumour development and
angiogenesis, although the exact molecular mechanisms of these
interactions are for the most part still unrevealed (Salehi et al,
2008). Securin has particularly been suggested to participate in
the regulation of chromatid separation during the metaphase–
anaphase interface of the cell cycle and to thus take part in
maintaining chromosomal stability (Tfelt-Hansen et al, 2006;
Bradshaw and Kakar, 2007; Salehi et al, 2008). According to
clinical studies, securin overexpression associates with the spread,
invasion and metastasis of cancer cells and predicts the outcome of
several malignancies (Boelaert et al, 2003; Ramaswamy et al, 2003;
Ito et al, 2008). In addition, overexpression of securin has been
related to endocrine therapy resistance in breast cancer (Ghayad
et al, 2009).
Securin has also been reported to be overexpressed and
associated with disease outcome in invasive breast carcinomas
(Sa ´ez et al, 1999; Solbach et al, 2004; Ogbagabriel et al, 2005).
Our previous paper implied the prognostic value of securin on
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sthe basis of a cDNA gene expression analysis, and immuno-
histochemical analyses further suggested that securin might
intensify the prognostication of patients with aggressive disease
(Talvinen et al, 2008). This paper extends the prognostic value of
securin immunohistochemistry in invasive breast cancer on the
basis of patient material (n¼310) obtained during a mammo-




The study comprises a total of 310 unselected patients diagnosed
with invasive breast cancer and treated in the Jyva ¨skyla ¨ Central
Hospital, Finland, during 1987–1997 when mammographic
screening was systematically practised in Central Finland. Treat-
ment of all patients included resection or mastectomy with axillary
evacuation, and adjuvant treatment with anti-oestrogen and/or
cytostatic drugs depending on the patient’s age, hormone receptor
status and axillary lymph node status at the time of diagnosis. No
pre-operative adjuvant treatment was administered. Patients were
followed up for an average of 10.5 post-operative years. Causes of
death were based on autopsy reports, death certificates and patient
files from the Finnish Cancer Registry. Complete clinical and
follow-up data are summarised in Table 1.
Tissue microarrays
The histological material of each breast cancer patient were
arranged in tissue microarrays (TMAs). The representative breast
cancer area from routinely formalin-fixed and paraffin-embedded
breast cancer blocks from archive material was identified. Two
tissue cores (diameter 0.6mm, min height 5mm), one from the
centre and the other from the edge of the representative breast
cancer area of each paraffin block, were punched and precisely
arranged into three TMA blocks with 238–258 cores in each, as
presented by Kononen et al (1998).
Immunohistochemical methods
Immunostainings of securin and Ki-67 were applied on 3mm
formalin-fixed and paraffin-embedded TMA sections according to
the standard procedure using the automated immunostaining
machine, LabVision Autostainer 480 (Thermo Fisher Scientific,
Fremont, CA, USA). Antigen retrieval was performed in a micro-
wave oven at 991C for 10 (securin) or 15 (Ki-67)min in a citrate
buffer (Dako REAL Target Retrieval Solution, Dako, Glostrup,
Denmark, S2031, 1:10). Antibodies were applied at concentrations
of 1:50 (securin, clone DCS-280, ab3305, Abcam, Cambridge, UK)
and 1:100 (Ki-67, 18-0192, Zymed, Invitrogen, Carlsbad, CA,
USA). Detection was performed using a PowerVisionþ polymer
Kit according to standard protocols (DPVBþ110HRP, Immuno-
Vision Technologies, Vision BioSytems, Norwell, MA, USA) with
diaminobenzidine as chromogen. All malignant cells of each tissue
cylinder were counted. Positively stained securin and Ki-67 nuclei
were registered as a fraction (%) of the number of tumour cells. In
our previous paper, we presented intraclass correlation coefficients
for intra- and interobserver reproducibilities of securin and Ki-67
immunoevaluations (ICC 0.51–0.96) (Talvinen et al, 2008).
Statistical analysis
To explore the prognostic value of securin and Ki-67, we
elaborated a threshold based on follow-up information of the
patient material by screening with univariate analyses and
selecting points of strongest prognostic value. Selected cut-off
points were confirmed by receiver operating characteristic
analysis. To evaluate the potential of securin to intensify the value
of Ki-67 in breast cancer prognostication, we analysed all possible
combinations of low and high expressions of both securin and Ki-
67 immunopositivity by forming four classes of patients: low
securin and low Ki-67, high securin and low Ki-67, low securin and
high Ki-67, and high securin and high Ki-67.
The present analysis allowed us to estimate the consistency
related to the histological TMA method by comparing results from
tissue punches representing different areas of the specimen, one
punch from the centre and another from the periphery of the
tumour. Comparison of immunopositivity of the central and
peripheral tumour areas showed moderate consistency (ICC 0.737
for securin and 0.887 for Ki-67). Moreover, McNemar’s test of
marginal homogeneity (P¼0.63 and P¼0.45 for securin and
Ki-67, respectively) and kappa coefficients (k¼0.59 and k¼0.69
for securin and Ki-67, respectively) showed concordance between
central and peripheral tissue cores. The observed acceptable
consistencies between the results of central and peripheral tumour
areas allowed us to apply for final prognostic analyses either the
mean of the results of the two tissue cores (65% of cases) or a
single observation. A single observation was used if only one tissue
core was representative of cancer cells.
Survival analysis was performed to investigate the prognostic
value of securin and the association between securin and Ki-67 in
evaluating breast cancer outcome. The cumulative percentages for
breast cancer-specific mortality were estimated using the Kaplan–
Meier technique and the differences between categorised values
were tested using the log-rank test. Differences between categories
were quantified by calculating hazard ratios (HRs) with 95%
confidence intervals (95% CIs) using Cox’s regression models.
Cox’s regression models with multiple explanatory variables were
used to adjust the results for axillary lymph node status classified
as node-positive and node-negative cases, with patient’s age and
tumour size as continuous variables. An adjusted analysis was
made separately for securin, Ki-67 and the variable established by
the combination of the two. Patients with missing data were
Table 1 Clinicopathological characteristics of patient material (n¼310)
Age at diagnosis (years)
Mean (min to max) 58 (49–78)
Tumour diameter (cm)
Mean (s.d.) 2.3 (1.4)
Follow-up time (years)
Mean 10.5
(Min to max) (0.2–19.9)
Tumour size
Small (p3cm) 74% (n¼229)




Other types 7% (n¼22)
Axillary nodal status
Node   46% (n¼142)
Node + 45% (n¼141)
Ki-67 status
Low (o10%) 42% (n¼130)
High (X10%) 49% (n¼153)
Causes of death during follow-up
Breast cancer 18% (n¼55)
Other 20% (n¼61)
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sexcluded from analyses. P-values less than 0.05 were considered
to be statistically significant. All statistical computations were
performed using SAS System for Windows, Version 9.1.3 and SAS
Enterprise Guide 4.1. (SAS Institute Inc., Cary, NC, USA).
RESULTS
Table 2 summarises the results of securin and Ki-67 immuno-
histochemistry in 310 cases of invasive breast cancer and in
patient subgroups divided according to tumour histology and
Ki-67 status. The observed fraction of securin immunopositivity
was systematically lower than that of Ki-67 throughout all cases
and prognostic subgroups. Screening with univariate survival
analyses and selecting points of strongest prognostic value set
an optimal cut-off point at 1.5% for securin immunopositivity.
This cut-off point produced two patient groups, which, with the
highest statistical significance, identified patients who were alive
with or who died of breast cancer during the follow-up period.
Receiver operating characteristic analysis of securin immuno-
histochemistry validated the selected cut-off point. The same
methods confirmed the established threshold of 10% immuno-
positivity as the optimal cut-off point for Ki-67 in our study
(Tavassoli and Devilee, 2003, p 19).
Figure 1 shows the potential of securin to separate the patients
into groups of favourable and unfavourable outcome of breast
cancer on the basis of a cut-off point of 1.5% immunopositivity
(P¼0.004). Similarly, the prognostic significance of securin was
shown in subgroups of invasive ductal histology (P¼0.010), and
with small and large tumour size (P¼0.034 and P¼0.033 for
tumour diameters p3cm and 43cm, respectively). The results of
Cox’s univariate survival analyses are interpreted as a comparison
of the survival between groups of patients associated with securin
and Ki-67 immunopositivity above and below the determined cut-
off points at 1.5 and 10%, respectively. On the basis of an analysis
of all cases and subgroups of ductal histology of breast cancer,
securin predicted the survival of disease with statistical signifi-
cance (Table 3). In comparison with the prognostic values of
securin and Ki-67, univariate Cox’s survival analysis for securin
indicated a 2.9-fold (P¼0.006, 95% CI 1.3–6.0) and for Ki-67 a
2.4-fold risk of breast cancer death (P¼0.004, 95% CI 1.3–4.5). In
a combination of securin and Ki-67, the observed risk of breast
cancer death was 5.8-fold (securinX1.5 and Ki-67X10% vs
securino1.5 and Ki-67o10%, P¼0.004, 95% CI 1.8–18.9). In
addition, when compared, the high to low securin immunoposi-
tivity risk for breast cancer death was 2.7-fold for patients with
small and 3.6-fold for patients with large tumour size (P¼0.042,
95% CI 1.0–7.0 and P¼0.046, 95% CI 1.0–12.4, respectively).
When the data of 310 breast cancer cases were adjusted for
nodal status, patient’s age and tumour size, securin immuno-
positivity still seemed to be a statistically significant predictor for
outcome of invasive breast cancer (Table 4). In this analysis, the
observed HR of breast cancer death was 2.3 for securin (P¼0.028,
95% CI 1.1–5.0). As expected, nodal status (P¼0.0004) and
tumour size (Po0.0001) were also significant predictors of breast
cancer death. The corresponding analysis of Ki-67 indicated a
similar prognostic potential, although statistical significance was
not quite attained in our study (P¼0.058, HR 1.9). The highest
prognostic value was associated with the combination of securin
and Ki-67, which predicted a 4.3-fold risk for breast cancer death
Table 2 Summary of mean fractions (%) and standard deviations
(in parentheses) of securin and Ki-67 immunopositive nuclei
Securin Ki-67
All 6.1 (6.8) 15.0 (14.2)
Ki-67, o10% 3.3 (4.1) 4.5 (2.6)
Ki-67, X10% 8.6 (7.3) 24.0 (14.0)
IDC 6.4 (6.9) 16.0 (14.8)
Ki-67, o10% 3.5 (4.3) 4.8 (2.5)
Ki-67, X10% 8.5 (7.3) 24.5 (14.5)
The results are based on all patients with invasive breast carcinoma (n¼310) and on
subgroups divided according to invasive ductal histology (IDC) and Ki-67
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Figure 1 Kaplan–Meier curves of breast cancer survival based on
securin immunohistochemistry in 310 breast cancer patients. Securin
immunohistochemistry (positivity o1.5% (A) vs X1.5% (B) of cancer cell
nuclei) distinguishes patients with a different outcome of disease
(P¼0.004).
Table 3 Summary of Cox’s univariate analyses on securin immuno-
positivity performed in invasive breast carcinomas and in subgroups divided
according to invasive ductal histology (IDC) and Ki-67 immunopositivity
(low, o10%; high, X10%)
nP HR 95% CI
All 310 0.006 2.9 1.3–6.0
Ki-67o10% 130 0.057
Ki-67X10% 153 0.523
IDC 252 0.014 2.9 1.2–6.8
Ki-67o10% 101 0.064
Ki-67X10% 134 0.626
The results are based on the optimal cut-point determined at 1.5% of securin
immunopositivity, derived from analysis of breast cancer-specific survival of the
patient data.
Table 4 Summary of multivariate Cox’s regression analyses of securin
immunoexpression performed in invasive breast carcinomas and in
subgroups divided according to invasive ductal histology (IDC) and Ki-67
immunopositivity (low, o10%; high, X10%)
nP HR 95% CI
All 257 0.028 2.3 1.1–5.0
Ki-67o10% 106 0.031 5.1 1.2–22.7
Ki-67X10% 134 0.617
IDC 211 0.051
Ki-67o10% 84 0.024 13.1 1.4–121.3
Ki-67X10% 118 0.719
The results are based on the optimal cut-point determined at 1.5% of securin
immunopositivity, derived from analysis of breast cancer-specific survival of the
patient data. Axillary lymph node status, patient’s age and tumour size at the time of
diagnosis were used as covariates in multivariate analyses.
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sin our study (P¼0.017, 95% CI 1.3–14.2). In addition, in the
subgroup having low proliferative activity (Ki-67o10%), securin
predicted a 5.1-fold risk of breast cancer death (P¼0.031, 95% CI
1.2–22.7). Further analysis of patients with low Ki-67 positivity
and invasive ductal histology associated securin immunohisto-
chemistry with a 13.1-fold risk of breast cancer death (P¼0.024,
95% CI 1.4–121.3). Similarly, securin immunopositivity predicted
the disease outcome among patients with large tumour size
(43cm in diameter) when adjusted for patient’s age and nodal
status (P¼0.040, HR 3.8, 95% CI 1.1–13.7).
DISCUSSION
Securin is a recently recognised oncogene with multiple known
functions in the tumourigenesis and progression of malignant
diseases, especially in the regulation of chromosome integrity in
cell proliferation. In breast cancer research, knowledge about
securin is fast accumulating, but to date, there are no published
prognostic studies on securin in invasive breast cancer patients
with long-term follow-up.
Our results suggest that securin immunohistochemistry is an
independent prognosticator of invasive breast cancer. This finding
is in concordance with our previous paper comprising a small
sample size of aggressive breast carcinomas with a high prolifera-
tion rate (Talvinen et al, 2008). In this paper on 310 breast cancer
patients with a long-term follow-up, low securin immunopositivity
indicated a favourable course of disease, especially in association
with low Ki-67 immunopositivity. In our results, the combination
of high immunopositivity for both securin and Ki-67 indicated a
4.3-fold risk of breast cancer death as compared with the
prognostic value of low securin and Ki-67, suggesting that securin
in combination with Ki-67 enhances the prognostic information
derived from cell proliferation. In the light of our results, securin
may prove to be a valuable prognostic factor for clinical pathology,
although the present data do not yet allow for testing of the
possible prognostic value of securin in relation to the gold
standard of breast cancer prognostics, the Nottingham Prognostic
Index (Elston and Ellis, 1991).
According to literature, securin is involved in the regulation of
cell cycle as a mitotic check-point gene, functioning in the
metaphase–anaphase transfer (Hagting et al, 2002). Securin is
critical for genetic stability, as it inhibits premature sister
chromatid separation. In detail, during metaphase, cohesin binds
sister chromatids and degradation by separase is necessary to
enable sister chromatid separation at anaphase (Ciosk et al, 1998;
Nasmyth, 2005). According to present knowledge, securin is
involved in arresting metaphase by binding to separase, preventing
cohesin degradation and thus blocking chromatid separation
(Waizenegger et al, 2002; Nasmyth, 2005). Despite this biological
understanding of the function of securin during a normal cell
cycle, the role of securin in the proliferation of malignant cells is
still unsettled. Some investigations suggest that securin over-
expression could reduce cell proliferation by arresting mitosis
(Yu et al, 2000). Others have speculated that securin could function
in cell proliferation through the induction of apoptosis and delay
of mitosis (Akino et al, 2005). Inhibition of sister chromatid
separation, in turn, suggests that securin is responsible for uneven
chromatid separation and induction of aneuploidy in tumouri-
genesis and tumour progression (Tfelt-Hansen et al, 2006; Vlotides
et al, 2007; Salehi et al, 2008). Available clinical studies, however,
demonstrate a strong correlation between securin expression
and cell proliferation in different malignancies (Heaney et al, 2002;
Tsai et al, 2005; Filippella et al, 2006; Genkai et al, 2006; Zhu
et al, 2006).
As a proliferation marker, securin clearly differs from estab-
lished markers of cell proliferation in clinical pathology. The
established proliferation markers, Ki-67 and proliferating cell
nuclear antigen (PCNA), are expressed in all phases of the cell
cycle (Takasaki et al, 1981; Guillaud et al, 1989; van Oijen et al,
1998). In comparison with these, securin concentrates on a specific
phase of the cell cycle, the expression gradually increasing during
the S phase with a peak at G2/M (Yu et al, 2000; Chen et al, 2005;
Chao and Liu, 2006). According to many investigations, specific
fractions of the cell cycle might provide relevant information on
the behaviour of different malignancies. Therefore, markers of
selected phases of the cell cycle could prove beneficial for
individual breast cancer patients in intensifying the value of
established proliferation markers (Heidebrecht et al, 1997;
Rudolph et al, 1999, 2001). Prognostication of breast cancer is at
the moment based on Ki-67 immunohistochemistry, which has
been proven to have strong prognostic correlations (Bouzubar
et al, 1989; Veronese et al, 1993). Our paper suggests that the appli-
cation of securin alone or in combination with other proliferation
markers could contribute to the prognostication of invasive
breast cancer.
The observed average level of securin immunopositivity in our
present results differs from that of our previous study (Talvinen
et al, 2008). The obvious explanations lie in the different patient
selection procedure and histological material. The present patient
data comprise mammographic screening cases characterised by
early cancer detection, modern diagnostic and therapeutic
methods, and long-term follow-up. Moreover, the type of
histological material is an important feature in the observed
securin expression. At present, TMAs are also established for
staining for cell proliferation (Hoos et al, 2001; Garcı ´a et al, 2003;
Couvelard et al, 2009). However, some publications address the
possible influence of field selection of TMAs on the observed
immunopositivity, especially with regard to uneven staining and
expression patterns (Gillett et al, 2000; Wa ¨rnberg et al, 2008;
Couvelard et al, 2009). This is of special interest with regard to the
expression of proliferation markers, which is, according to many
investigators, concentrated in ‘hot spots’, that is, the most cellular
and invasive front at the periphery of the tumour (Jannink et al,
1995; Belie ¨n et al, 1999, Salminen et al, 2005). Thus, TMA punches
do not necessarily represent the most proliferative tumour area
and, therefore, the highest securin and Ki-67 expression of the
tumour might not be evaluated in this study. This does hamper
comparison between reports but does not, however, influence the
prognostic conclusions based on a single study with consistent
histological and immunohistochemical methods.
In summary, this paper introduces securin as a prognostic
factor of breast cancer-specific survival, independent of patient’s
age, nodal status and tumour size. In combination with Ki-67
immunohistochemistry, securin further intensified the prognos-
tic value of cell proliferation. Although the cut-off point may
not directly be applicable to clinical material in whole sections,
our results on TMA suggest that minimal or absent securin
immunopositivity could indicate a more favourable outcome of
disease than that concluded from Ki-67 immunopositivity alone.
Securin is a recently published oncogene with multiple functions
in tumourigenesis and progression, invasion, and metastasis of
malignant disease, and, therefore, further investigations are
needed to evaluate the possible prognostic and therapeutic
applications of securin in treatment decisions of individual
breast cancer patients.
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